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To study conformational transitions at the muscle nicotinic acetyl-
choline (ACh) receptor (nAChR), a rhodamine fluorophore was
tethered to a Cys side chain introduced at the 19 position in the
M2 region of the nAChR expressed in Xenopus oocytes. This
procedure led to only minor changes in receptor function. During
agonist application, fluorescence increased by (FF) 10%, and
the emission peak shifted to lower wavelengths, indicating a more
hydrophobic environment for the fluorophore. The dose–response
relations for F agreed well with those for epibatidine-induced
currents, but were shifted 100-fold to the left of those for
ACh-induced currents. Because (i) epibatidine binds more tightly to
the -binding site than to the  site and (ii) ACh binds with
reverse-site selectivity, these data suggest that F monitors an
event linked to binding specifically at the -subunit interface. In
experiments with flash-applied agonists, the earliest detectableF
occurs within milliseconds, i.e., during activation. At low [ACh] (<
10 M), a phase of F occurs with the same time constant as
desensitization, presumably monitoring an increased population
of agonist-bound receptors. However, recovery from F is com-
plete before the slowest phase of recovery from desensitization
(time constant 250 s), showing that one or more desensitized
states have fluorescence like that of the resting channel. That
conformational transitions at the -binding site are not tightly
coupled to channel activation suggests that sequential rather than
fully concerted transitions occur during receptor gating. Thus,
time-resolved fluorescence changes provide a powerful probe of
nAChR conformational changes.
The muscle nicotinic acetylcholine receptor (nAChR) is a wellstudied member of the Cys-loop family of neurotransmitter-
gated ion channels. A 4.6-Å structure (1) shows five 160-Å-
long rod-shaped subunits surrounding a central channel. From
the extracellular side the subunits have a counterclockwise order
of  (2, 3). Each subunit has a large extracellular N-
terminal or ligand-binding domain followed by four transmem-
brane regions, M1–M4 (4). The structure of the extracellular
ligand-binding sites, at the  and  interfaces, resembles that
of a homologous molluscan ACh-binding protein (3). Numerous
biochemical and electrophysiological experiments indicate that
M2 lines the channel (5).
The nAChR exists in at least four distinct, interconvertible
conformational states: resting, open, fast-onset-desensitized,
and slow-onset-desensitized (6). The open and the fast-onset-
desensitized states presumably have moderate affinity for ACh,
are metastable (on millisecond time scales), and are present in
low concentrations at equilibrium. The supralinear dose–
response relation (Hill coefficient 1) suggests that the open
state of the channel is much more likely to be associated with the
presence of two bound agonist molecules than with a single
bound agonist (7). In the prevailing kinetic scheme, receptors in
the resting state bind two agonist molecules, isomerize to the
open state, and in the continued presence of agonist, desensitize.
After removal of agonist, the agonist–receptor complex disso-
ciates and the channel closes within milliseconds; but desensi-
tized receptors isomerize more slowly to the resting state (tens
of milliseconds to hundreds of seconds). Thermodynamic con-
siderations suggest that the resting state has low affinity for
agonist, whereas the slow-onset-desensitized state is the most
stable state in the presence of agonist because of its high affinity.
Kinetic analyses of single-channel and macroscopic function
suggests that in the resting state, the affinity of ACh for the two
sites differs by a factor of 30 (8). Experiments with partially
assembled  and  dimers or with fully assembled, pentameric
-less or -less receptors show that the  site has the higher
affinity for ACh or carbamylcholine (9–11). Interestingly, epi-
batidine binds with 75-fold higher affinity to the  site (10).
To learn more about the changes in state andor conforma-
tion, one requires a structural probe that reveals changes in real
time as receptors proceed through electrophysiologically defined
states. Covalently bound fluorescent probes have proven useful
for this purpose at other ion channels and, recently, for -ami-
nobutyric acid type C receptors as well (12). We have now
covalently modified a Cys at the extracellular end of M2 with a
thiol-reactive fluorophore, and we report f luorescence changes
during receptor activation and desensitization. This report be-
gins the analysis of these changes.
Materials and Methods
Reagents and Solutions. The fluorescent dye sulforhodamine
methanethiosulfonate (MTSR) and the blocking reagent Na
(2-sulfonatoethyl) methanethiosulfonate were purchased from
Toronto Research Chemicals. The photoisomerizable agonist
3,3-bis-[-(trimethylammonium)methyl]azobenzene (Bis-Q)
was prepared (13). Other reagents, including ()-epibatidine,
were purchased from Sigma. The full-Na recording solution,
ND-96, contained 96 mM NaCl, 2 mM KCl, 1 mM MgCl2, and
5 mM Hepes (pH 7.4). For low-Na recording solution, NaCl was
partially replaced with equimolar N-methyl-D-glucamine. The
incubation solution contained ND-96 solution plus 1.8 mM
CaCl2, 0.6 mM theophylline, 2.5 mM pyruvic acid, 50 gml
gentamycin, and 5% horse serum.
Molecular Biology. A pSP64T construct encoding the nAChR
-subunit with an A272C mutation (the M2 19 position) was
obtained from A. Karlin. A 714-bp BstEIIBspEI fragment was
transferred to the corresponding site of a pAMV construct
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encoding the wild-type -subunit. Capped mRNA for the em-
bryonic mouse muscle nAChR subunits were prepared by in vitro
runoff transcription (Ambion mMagic mMessage).
Oocyte Preparation and mRNA Injection. Stage VI oocytes of Xe-
nopus laevis were harvested (14) and injected with 30 ng of
mRNA at a subunit ratio 2:1:1:1 :::. To achieve the high
levels of expression required for detection of the fluorescent
label over the background fluorescence (caused by oocyte
autofluorescence and by nonspecific binding of dye), oocytes
were incubated for 6–8 days at 18°C.
Fluorescent Labeling. Oocytes were rinsed and then reacted with
10 mM Na (2-sulfonatoethyl) methanethiosulfonate for 90 s to
block endogenous surface sulfhydryl groups, terminated by 5
mgml BSA. Cys at the M2 19 position does not react with Na
(2-sulfonatoethyl) methanethiosulfonate (15). After a wash, the
oocytes were labeled with 5 M MTSR plus 100 M ACh for
45 s, terminated by a 5 mgml BSA solution. BSA, Na (2-
sulfonatoethyl) methanethiosulfonate, and MTSR reagents were
made up in ND-96 just before use, and all steps were performed
on ice. Labeled oocytes were stored in incubating solution at 4°C
for up to 72 h after labeling.
Spectral Analysis. Emission spectra from oocytes were obtained
with a spectrograph and intensified charge-coupled device cam-
era combination as described (16). Excitation filter was
535DF35, dichroic mirror was 565DRLP; no emission filter was
used. Emission spectra of free MTSR dissolved in ethanol and
ND98 were obtained with an SLM-Aminco fluorometer (SLM
Instruments, Urbana, IL).
Simultaneous Recording of Current and Fluorescence Intensity. In the
inverted fluorescence microscope fitted with a high-Q tetra-
methylrhodamine isothiocyanate filter set (Chroma Technology,
Rockingham, VT), a 40 objective lens (N.A. 0.7, working
distance 510 m), and a photomultiplier tube (R928P, Photon
Technology International, Lawrenceville, NJ) (17), a black block
0.4 mm high bearing a vertical slit 0.75 mm wide exposed the
animal pole of the oocyte to both the perfusion solution and the
beam from the 100-W Hg lamp (17). This arrangement allowed
efficient perfusion of nearly the entire oocyte surface, including
the optically monitored area at the top of the slit.
Two-electrode voltage clamp procedures were used (Gene-
Clamp 500, Axon Instruments). The holding potential was 80
mV (ACh recordings) or60 mV (epibatidine recordings). With
ND-96, the average 1-M ACh response of a batch of oocytes
expressing A19C nAChR (19C) was 200–1,000 nA before
MTSR labeling, suggesting extrapolated responses of 40–200 A
to saturating doses of ACh. These currents cannot be measured
accurately with our circuits; therefore, where indicated, re-
sponses were measured in low-Na recording solution.
Current and fluorescence traces were acquired at 40 Hz with
an Axon Digidata interface and pCLAMP8. The fluorescence
signal was filtered at 5 Hz by an eight-pole low-pass filter, then
subjected to further digital filtering (1–2 Hz eight-pole Bessel)
and baseline adjustment where appropriate. Waveforms were
fitted to single or double exponentials with routines in ORIGIN 7
and CLAMPFIT 8. Dose–response relationships were fit to the Hill
equation by using ORIGIN 7. All current and fluorescent mea-
surements are presented as mean  SE.
cis-Bis-Q Photoisomerization. For light-f lash experiments, a beam
splitter (FC70, Rapp OptoElectronic) directed light from a Xe
flashlamp (JML-C1, Rapp OptoElectronic, filtered by Schott
GG375, BG12, and KG5, yielding 410–450 nm) and from the Hg
fluorescence illuminator (with Chroma Technology HQ545
30 exciter filter) to the fluorescence cube and a 20 objective
lens, N.A. 0.75. Signals were acquired at 20 kHz and then filtered
at 1 kHz.
Results
Fluorescent Labeling of A19C nAChR. It is convenient to renumber
the amino acid sequence of M2 segments lining the nAChR
channel, so that 1 is near the cytoplasm and 20 is near the
extracellular solution (18). Ala-272 at the 19 position of M2
was mutated to Cys to allow modification with MTSR, a thiol-
reactive fluorophore. After labeling, 19C-injected oocytes
were twice as fluorescent as uninjected or WT nAChR-injected
oocytes (data not shown). ACh dose–response relations were
measured for WT-expressing oocytes and for labeled and unla-
beled 19C-expressing oocytes and showed no major changes;
WT, 19C, and MTSR-modified 19C had EC50s of 24  1,
35  1, and 43  4 M, respectively, and Hill coefficients of
1.44  0.04, 1.24  0.06, and 1.36  0.14, respectively (Fig. 1A).
However, MTSR labeling did subtly alter 19C receptor func-
tion. Measurements of the response at [ACh] 3 M before and
after labeling (Fig. 1C) indicated that whereas MTSR had little
or no effect on the WT response (decrease of 15 15%, n 4),
it enhanced the 19C current response by 528  107% (n  3);
Fig. 1. Effects of MTSR labeling on nAChR electrophysiology. (A and B)
Traces, dose–response relations, and fits to the Hill equation for WT-, 19C-,
or MTSR-labeled 19C by using either ACh (A) or epibatidine (B). The bars
show agonist application at the indicated concentration (M). The epibati-
dine dose–response relation for MTSR-labeled 19C was determined by
administering only two doses of epibatidine to each oocyte, a single test dose
(0.1–6M, n 4–8 oocytes per dose), and a saturating dose (30M). The ACh
dose–response relations were determined by administering seven to eight
concentrations to each of three to four oocytes. Apart from the ACh experi-
ments with 19C- and MTSR-labeled 19C, the experiments shown in A and
B were completed with oocytes expressing high levels of receptor by using
solutions with 20% of normal [Na] (N-methyl-D-glucamine substitution). (C)
Effects of MTSR labeling on the response waveform. The response to 1M ACh
was measured before and after labeling with 5 M MTSR in the presence of
100 M ACh. These experiments used normal [Na]. The box summarizes the
changes in the peak IACh, calculated as [(IACh, preMTSRIACh, postMTSR)  1]  100.
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thus, the responses to 1 and 3 M ACh were greater than the
values predicted by fits of the Hill equation (Fig. 2D). The
response waveforms before and after modification also show that
MTSR modification increased the rate of 19C desensitization.
Further indications of altered receptor function come from
the dose–response relation for epibatidine. Whereas WT and
19C had EC50s of 13.1  1.1 M and 14.8  1.8 M
epibatidine, respectively, the EC50 for MTSR-labeled 19C was
one order of magnitude lower, 1.11  0.11 M (Fig. 1B). The
Hill coefficients showed only slight changes; WT-, 19C-, and
MTSR-labeled 19C had Hill coefficients of 0.93 0.05, 1.10
0.11, and 1.22  0.12, respectively. These changes in nAChR
function may occur because MTSR labeling increased the affin-
ity of the  site for agonist (see below).
ACh-Mediated Changes in Fluorescence Intensity. Simultaneous
measurements of current and fluorescence intensity indicated
(Fig. 2A) that agonist application resulted in increased fluores-
cence (F). Such a F never occurred with control oocytes. At
low doses of ACh (10 M), F was biphasic. In bath applica-
tion experiments, the faster phase (Ff) was indistinguishable
from the time course of the current responses, which in turn
cannot be distinguished from the time course of solution change
near the oocyte. The slower phase (Fs) was similar to that of
desensitization (Fig. 2A; analyzed in Fig. 5 below). At [ACh] 
10 M, F reached its maximum magnitude (average FF
10%) and consisted of a single component that increased with
the same time course as the rise of the current, with no further
change in fluorescence intensity during desensitization (Fig. 2 B
and C). To measure the dose–response relation of Ff (Fig. 2D),
f luorescence intensity was determined at peak current. Although
Ff was simultaneous with the rising phase of the current
response, it clearly did not correlate with activation; with ACh,
the EC50 for Ff (266  43 nM, Hill coefficient  0.53  0.04)
was two orders of magnitude lower than the EC50 for the current
response (43  4 M). Thus, ACh-mediated Ff corresponds to
a transition that reaches full occupancy at [ACh] much less than
the EC50 for activation.
Photoisomerization of cis-Bis-Q Reveals ThatF Is Complete Within 20
ms. We used1-ms light flashes to jump the concentration (Fig.
3) of the photoisomerizable agonist trans-Bis-Q (19). The flash-
induced I was fitted by a single exponential with  5.5 and 5.3
ms for 19C and WT, respectively. As perfusion continued with
the inactive cis-Bis-Q isomer, I decayed (  2.6–2.9 s) due to
washout and diffusion of trans-Bis-Q as well as desensitization
(data not shown). A F (1.8%) was seen for 19C (Fig. 3) but
not WT-expressing oocytes (data not shown). The absolute
flash-induced F was comparable with F for bath-applied
trans-Bis-Q; but background fluorescence was larger, because we
recorded from the vegetal pole, which is more resistant to light
flashes but is also approximately five times more autofluores-
cent. Thus, a component of F is complete within 20 ms after an
agonist concentration jump, one to two orders of magnitude
faster than Bis-Q-mediated desensitization.
Epibatidine-Mediated Ff Corresponds to a Step Tightly Coupled to
Channel Activation. Compared with ACh and carbamylcholine,
epibatidine activates muscle nAChR with unique site-selectivity
(10). We tested the dose–response relation of Ff by using
epibatidine as the agonist. To compare the current and fluores-
cence responses to the two agonists, individual, MTSR-labeled,
19C-injected oocytes were perfused with a saturating dose of
ACh and, after allowing for recovery, a saturating dose of
epibatidine (Fig. 4A). Epibatidine was a partial agonist; 30 M
epibatidine (a dose 27 times greater than EC50) elicited currents
Fig. 2. ACh-induced Ff occurs during a transition simultaneous with, but
distinct from, channel activation. (A) At low [ACh], the onset of F was
biphasic. ACh-induced current andF were recorded simultaneously at several
[ACh] (traces are superimposed). The horizontal bars above the current re-
sponses indicate application of agonist. (B) Another oocyte. At high [agonist],
the onset ofF was monophasic and did not correlate with channel activation.
(C) At [ACh]  10 M, there were no detectable changes in fluorescence
during desensitization. (D) Dose–response relations and fits to the Hill equa-
tion for the peak ACh-induced current (from experiments like those of Fig. 1)
and for Ff, the magnitude of the fluorescence shift at the time of the peak
ACh-induced current (n  3–12 responses per dose). The dose–response rela-
tion for Ff was normalized to the value for full F response of a saturating
dose (10 M ACh). [Na] was 20% of normal.
Fig. 3. Current and fluorescent responses to flash-photoisomerization of
cis-Bis-Q. Oocytes expressing MTSR-labeled 19C were perfused with 1 M
cis-Bis-Q ( 99% cis), eliciting a 160-nA current (data not shown); photoi-
somerization (a 1-ms flash 5 s after start of cis-BisQ perfusion) elicited a
765-nA current. Control traces were averaged from data before perfusion of
cis-Bis-Q and after washout, then were subtracted from the trace during
cis-Bis-Q. A shutter protecting the photomultiplier tube was closed before the
flash, resulting in a 9-ms gap in the fluorescence data.
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from MTSR-labeled 19C that were 0.23 0.02 (n 4) of that
elicited by 1,000 M ACh (a dose 23 times greater than EC50).
Saturating doses of both agonists, however, elicited similar
increases in fluorescence intensity; the magnitude of the epiba-
tidine F was 1.08 0.24 (n 3) that of the ACh F, suggesting
that the two agonists mediate similar changes in the fluorophore
environment. Interestingly, whereas ACh elicited a biphasic F
only at low doses, epibatidine produced a biphasic F at all doses
tested. At saturating doses of agonist, the epibatidine Ff was
only 0.63  0.10 (n  3) of the ACh Ff. A more striking
difference was in the dose–response relation for Ff (Fig. 4C).
Whereas with ACh the EC50 for Ff and for current activation
differed by two orders of magnitude, with epibatidine, the EC50
for Ff and for current activation were indistinguishable at
0.99  0.15 M and 1.11  0.11 M, respectively. The Hill
coefficient for Ff was 1.13  0.16.
The Slower Phase of the Fluorescence Shift Correlates with Desensi-
tization. Time constants determined by fitting the desensitization
component of the current waveform with a single exponential
function were compared with the slower of the two time con-
stants derived from fitting the entire, matching F waveform
with a double exponential function. Despite considerable vari-
ability in desensitization time constants, for both ACh and
epibatidine (Fig. 5 A and B), there is good agreement between
the time constant for Fs and for current desensitization over a
20-fold range (3–70 s).
Recovery of Fluorescence Baseline Is Faster than Recovery from the
Desensitized State. Upon removal of agonist the current decays
faster than the fluorescence signal (Fig. 6A), suggesting that at
least one short-lived (several seconds) desensitized state is
Fig. 4. Epibatidine-induced Ff occurs during a transition closely linked to
channel activation. (A) Epibatidine evokes smaller maximal currents than ACh,
but a F similar in magnitude. Sequential saturating doses of ACh and epi-
batidine were administered and the current and F responses were superim-
posed. A representative trace is shown and the box summarizes comparisons
of ACh and epibatidine induced current,F, andFf. (B) Representative traces
of current and F responses to test and saturating doses of epibatidine. Bars
show duration of agonist application at the indicated [epibatidine] of the test
and saturating doses (M). The vertical bars to the right of the F response
indicate Ff magnitude. (C) Dose–response relations and fits to the Hill equa-
tion for epibatidine-induced current (determined as described in Fig. 1) and
Ff (n  4–8). [Na] was 50% of normal.
Fig. 5. Onset of Fs correlates kinetically with desensitization. ACh-induced
(A) or epibatidine-induced (B) F responses were fit with two exponentials
and the slower time constants were plotted against the time constants for
desensitization. The solid and dashed lines represent equality and twofold
differences, respectively. (A) , 0.3 M (n  4); , 1 M (n  25); E, 3 M
(n  17); ‚, 5 M (n  4). (B) E, 0.2, 0.5, and 1 M, (n  7); ‚, 3, 6, and 8 M
(n  7); , 10, 18, 25, and 30 M (n  8).
Fig. 6. Decay of F after removal of agonist. (A) Current (dotted line) and
fluorescence (solid line) decay after ACh washout was normalized and aver-
aged. [ACh] and duration and the number of traces averaged are indicated
above each trace. The traces were fitted to a single-exponential function with
the indicated time constants. (B Left) After three 1-s test pulses of 1 M ACh
at 28-s intervals, a desensitizing step of 10 M ACh was applied for 5 min,
followed by a 10-s wash and 1-s test pulses of 1 M ACh at 28-s intervals. To
minimize photobleaching, the Hg lamp shutter was closed during the desen-
sitizing step. A representative trace is shown. (Right)E, plot of recovery of the
current response after desensitization; F, plot of return of fluorescence to
baseline. Fluorescence intensity was measured just before each test pulse. The
solid lines represent fits to a single exponential function with the indicated
time constants.
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f luorescent. To determine whether exit from the high-
fluorescence state correlates with exit from all physiologically
defined desensitized states, recovery from desensitization in-
duced by a prolonged (5-min) application of 10 M ACh was
monitored by means of brief (1-s) pulses of 1 M ACh at 28-s
intervals (Fig. 6B). The recovery of the fluorescence signal (F,
Fig. 6B) is measured only approximately; but fits to a single-
exponential function show a time constant several fold less than
that for the recovery of the current (E, 51  7 vs. 248  17 s,
respectively, n  5). These data indicate that, upon removal of
agonist, MTSR-labeled 19C also transiently occupies at least
one long-lived (several minutes) desensitized state that does not
show high fluorescence.
F Monitors an Increase in the Hydrophobicity of the Fluorophore’s
Local Environment. As solvent hydrophobicity increases, MTSR
emission intensity increases and the spectrum becomes blue-
shifted (	Ethanol  574 nm; 	ND98  584 nm). In the oocyte, a
desensitizing dose of ACh also increased the emission intensity
and blue-shifted the emission peak by 10 nm (Fig. 7A).
Therefore, F occurs because the fluorophore occupies a more
hydrophobic environment in the desensitized state than in the
resting state, rather than because a quencher moves away
(however, we cannot rule out the occurrence of both mecha-
nisms together). There were no spectral shifts with control
oocytes (Fig. 7B).
Discussion
In the standard kinetic scheme for nAChR activation, channel
opening follows the sequential binding of agonist at the  and
 sites. By using a fluorophore attached to the extracellular end
of nAChR M2, we detected one of the several agonist-induced
transitions. Which transition was detected?
A Scheme for the Observations. Fig. 8 shows a model that ratio-
nalizes our observations. In this scheme, a dagger (†) indicates
a high fluorescence state, and all † states are assumed to be
equally f luorescent. Both Ff and Fs occur when the fluoro-
phore senses a conformational change due to productive binding
of agonist to the  site. Because the  site is the high-affinity
site for ACh but the low-affinity site for epibatidine, these two
agonists are predicted to induce F at different regions of the
dose–response relation for agonist-induced currents.
This model accounts for many properties of the F response.
Because ACh has 30 times higher affinity for the  site (8),
AR† is fully occupied at [ACh] much lower than required for
fully occupying A2RO†. Assuming the MTSR labeling does not
markedly change the site selectivity of ACh and epibatidine, this
hypothesis explains how ACh EC50 for F and for I differ by
a factor of 160.
Epibatidine has reverse-site selectivity. Thus, epibatidine
binding to the  site occurs predominately during formation of
A2RO†, explaining why the EC50 for F and for I are indistin-
guishable with epibatidine.
What is the explanation for Fs? With ACh, Fs appears only
at agonist concentrations too low to saturate the  site. Under
these conditions, Fs represents equilibration among the various
comparably fluorescent R† states. More slowly, receptors enter
the slow-onset-desensitized A2D† state(s), pulling the entire
equilibrium to the right, and increasing the overall population of
R† states with a time constant equal to that of desensitization.
Thus, the time constants are equal for Fs and current desen-
sitization, not because the open and desensitized states differ in
fluorescence, but because the desensitized state(s) is one of the
fluorescent states and because desensitization is the rate-limiting
step for the equilibration, seen at low agonist dose, of the various
R† states. That flash-activation of trans-Bis-Q produces F
within 20 ms, much faster than desensitization, argues decisively
against a major role for even fast desensitization as the transition
that increases fluorescence.
Fig. 7. Spectral analysis of MTSR-labeled oocytes. (A) Fluorescence spectra
from an oocyte expressing 19C receptors in the absence or presence of a
desensitizing dose of ACh (500 M for 4 min.). ACh induced a reversible
leftward wavelength shift (584–574 nm) and an increase in fluorescence
intensity. (B) Difference emission spectra from uninjected, WT-injected, or
19C-injected oocytes. Spectra recorded in the presence of ACh were sub-
tracted from spectra recorded in the absence of ACh. Averages of four to five
cells (SEM 	 5% of full scale).
Fig. 8. Kinetic scheme accounting for F seen with ACh and epibatidine. F
is caused by conformational changes due to productive binding of agonist to
the  site. Because ACh and epibatidine show reverse-site selectivity for the
- and -binding sites, the state changes follow distinct pathways, labeled
A  ACh and A  epibatidine, favored by increasing concentrations of the
respective agonists. With ACh, F is due to formation of AR; with epibati-
dine, F is due to formation of A2Ro. R is the activatable receptor, A is the
agonist molecule, Ro is the open receptor, and D is the desensitized receptor.
 and  subscripts identify binding sites occupied by ligand. A dagger (†)
indicates a high-fluorescence state and a bracketed dagger an uncertain
assignment. Some states are in equilibrium with counterparts that have not
undergone conformational changes (not shown, for simplicity), accounting
for partial agonism.
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With epibatidine, Fs appears at all concentrations tested. We
propose that this arises because epibatidine is a partial agonist
(Fig. 4A); i.e., producing a limited population of receptors in the
A2RO† state. Therefore, the absolute flux from A2RO† to A2D†
is a rate-limiting step in the increase of the fluorescent receptor
population, even at saturating epibatidine concentration. Inter-
estingly, epibatidine shows different efficacies for evoking cur-
rent andFf, suggesting that it may bind more productively at the
 site than at the  site (see discussion of sequential confor-
mational changes below). Data for additional partial agonists
and antagonists will test this proposal.
The cyclical model for desensitization (7, 20, 21) incorporated
in Fig. 8 proposes that after releasing agonist, the receptor
remains functionally desensitized. Upon removal of a deeply
desensitizing dose of ACh, MTSR-labeled 19C returned to the
low-fluorescence state faster than functional recovery (Fig. 6),
suggesting the existence of a low-f luorescence-desensitized
state. In contrast to the resting state, ACh has little or no
site-selectivity for the ligand-binding sites of the desensitized
receptor (11, 22), and so agonist is released from the two sites
at similar rates. This finding suggests that low-fluorescence-
desensitized receptors are predominantly in the agonist-free
desensitized state rather than the monoliganded-desensitized
state.
Structural Basis of the Fluorescence Change. In Torpedo nicotinic
receptors, the 19 residues are nine residues and 10–14 Å from
the extracellular end of M2 (4). A fluorophore tethered to 19C
would be 35 Å from the ligand-binding site (23) and therefore
unlikely to monitor simple occupancy of the site. Although it is
possible that F is due solely to rearrangement of the N-terminal
ligand-binding domain, the authors (4) of an electron micro-
scopic structure suggested the presence of a conformational
change that accounts for F. In the resting state, the five M2
helices are separated by a water-filled space from the outer
protein wall formed by the M1, M3, and M4 helices. During
gating, the suggested rotation of M2 moves the 19 residue closer
to hydrophobic side chains in these other helices (4), leading to
the increase in fluorescence intensity and the blue shift in the
emission spectrum reported here. Presumably, ligand binding at
the  interface leads to conformational changes of their
respective M2 helices as well as of the M2 helix.
Gating Involves Sequential Conformational Changes. Because recep-
tors in the nAChR family (i) are (pseudo)symmetric multimers,
(ii) have ligand-binding sites 50 Å from the channel gate, and
(iii) display supralinear dose–response relations, models of
receptor function have been strongly influenced by ideas about
cooperative transitions in multisubunit regulatory proteins (24,
25). In the concerted model, positive cooperativity arises be-
cause sites on the same receptor are conformationally coupled.
In contrast, sequential models (26) propose that each binding
site changes its conformation upon agonist binding, with positive
cooperativity arising from the influence of this transition on the
neighboring binding site. With one ligand bound the receptor
adopts an intermediate state between resting and open.
This paper provides a way to define states of the nAChR. Our
present simultaneous electrophysiology and fluorescence mea-
surements indicate that the fluorophore detects conformational
changes in or around M2 after agonist binding at the 
interface. At low [ACh], we detected an intermediate state
comprising an  site in the active conformation and an  site
in the resting conformation, as revealed by the strong fluores-
cence response and weak current response. At low [epibatidine],
the major monoliganded intermediate state involves the  site,
which is not fluorescent. The straightforward interpretation of
these results is that in the MTSR-modified nAChR, subunits
undergo sequential rather than fully concerted transitions.
Fluorescent labeling of other nAChR residues and other
subunits may permit further detection and characterization of
conformational changes associated with movement of the chan-
nel gate during activation and desensitization. In conjunction
with structural studies, such knowledge will enhance our under-
standing of the structural transitions occurring during alloster-
ically controlled channel gating.
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